Advertisement
U.S. markets closed

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.7700-0.1800 (-4.56%)
At close: 04:00PM EDT
3.7500 -0.02 (-0.53%)
After hours: 06:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.9500
Open3.8965
Bid3.9300 x 900
Ask4.5000 x 1200
Day's Range3.7700 - 3.8999
52 Week Range2.5500 - 5.9700
Volume3,412
Avg. Volume5,316
Market Cap5.808M
Beta (5Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)-2.7100
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xenetic Biosciences, Inc.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more